Biomedical Sector Gains Momentum Amid Policy Support and US Relaxation
On.cc · 1 SOURCESabout 3 hours ago2 MIN
Summary
Hong Kong stocks are navigating near-term challenges as the extended National Day holiday period reduces mainland capital support, with the Hang Seng Index establishing a support band between 24,200 and 24,300. Trading volumes contracted to approximately HK$100 billion last Friday amid the absence of northbound capital flows. The biomedical sector has captured market attention as the leading performer, fueled by supportive policies from Beijing and improved relations with Washington regarding pharmaceutical investment. Market strategists see the sector transitioning from speculative trading toward sustained development driven by genuine business performance and international expansion capabilities.
Key Points
- The Hang Seng Index fell to a new correction low last Friday, with the 24,200-24,300 zone now serving as a critical support level
- Trading volume dropped to roughly HK$100 billion on Friday as mainland investors withdrew ahead of the extended National Day holiday
- Ten central government departments jointly released the 15th Five-Year Plan for Pharmaceutical Industry Development, designating biomedical as a strategic emerging pillar industry
- The policy targets call for innovative drug sector growth averaging over 20% annually by 2030, with first-in-class drugs comprising approximately 25% of the global total
- The United States is expected to relax biotech investment rules, allowing routine licensing deals between American and mainland pharmaceutical companies to continue
Why It Matters
The convergence of supportive domestic policies and potential easing of US restrictions marks a turning point for Hong Kong-listed biomedical companies that have faced prolonged regulatory uncertainty. This sector could provide sustained investment opportunities as companies transition from concept-driven to performance-driven growth, attracting both institutional and retail investors seeking exposure to China healthcare innovation story.
The convergence of supportive domestic policies and potential easing of US restrictions marks a turning point for Hong Kong-listed biomedical companies that have faced prolonged regulatory uncertainty. This sector could provide sustained investment opportunities as companies transition from concept-driven to performance-driven growth, attracting both institutional and retail investors seeking exposure to China healthcare innovation story.